New combo therapy for bone marrow disease enters early human testing
NCT ID NCT06502145
First seen Apr 05, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This early-phase study tests a new drug called iadademstat combined with a standard chemotherapy (azacitidine) for people with myelodysplastic syndrome (MDS), a bone marrow disorder. The main goal is to find the safest dose of iadademstat for future studies. About 12 adults with intermediate- to high-risk MDS will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.